Revolution Medicines (RVMD) Depreciation and Depletion (2022 - 2026)

Revolution Medicines has reported Depreciation and Depletion for 5 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion rose 37.5% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $8.0 million (up 29.03% YoY), and the FY2025 full-year result was $7.4 million, up 19.35% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $2.2 million, up from $2.1 million in the prior quarter.
• The five-year high for Depreciation and Depletion was $2.2 million in Q1 2026, with the low at $900000.0 in Q1 2022.
• Average Depreciation and Depletion over 5 years is $1.5 million, with a median of $1.4 million recorded in 2024.
• Peak annual rise in Depreciation and Depletion reached 50.0% in 2025, while the deepest fall reached 6.25% in 2025.
• Tracing RVMD's Depreciation and Depletion over 5 years: stood at $1.2 million in 2022, then increased by 8.33% to $1.3 million in 2023, then advanced by 7.69% to $1.4 million in 2024, then soared by 50.0% to $2.1 million in 2025, then advanced by 4.76% to $2.2 million in 2026.
• The last three Depreciation and Depletion figures came in at $2.2 million (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.

Peer Comparison